Edith Mitchell
Thomas Jefferson University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Edith Mitchell as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01818063 · Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast CancerSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer · principal investigator
- Ph1/Ph2NCT01349088 · Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast CancerSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · withdrawn · Breast Cancer, Metastatic Breast Cancer, Stage IV Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Sidney Kimmel Cancer Center LAPS Institutional CollaborationUG1CA233341 · NCI · THOMAS JEFFERSON UNIVERSITY · fiscal years 2019 to 2022 · $398,464 awarded in 2022Same name and institution; not confirmed by an ID
- PET Imaging of KRAS2 Activation to Guide EGFR Targeting in Cancer TherapyR01CA148565 · NCI · THOMAS JEFFERSON UNIVERSITY · fiscal years 2010 to 2013 · $519,862 awarded in 2013Same name and institution; not confirmed by an ID
- SPECIAL POPULATIONS NETWORK FOR CANCER CONTROLU01CA086127 · NCI · THOMAS JEFFERSON UNIVERSITY · fiscal years 2000 to 2003 · $392,272 awarded in 2003Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:09 UTC. The ranking covers the 200 most relevant of 161 PubMed records, and a shared surname and initials can bring in a namesake. All 161 on PubMed
- 1,815 citationsRCR 41.3
- A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.J Clin Oncol · 2009686 citationsRCR 15.4
- 603 citationsRCR 14.2
- Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.N Engl J Med · 2023528 citationsRCR 46.6
- 375 citationsRCR 9.5
- 358 citationsRCR 8.9
- 327 citationsRCR 10.5
- Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.Br J Cancer · 2004317 citationsRCR 7.1
- Effect of Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety: A Randomised Double-blind Placebo-controlled Trial.EBioMedicine · 2017299 citationsRCR 13.8
- A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial.J Allergy Clin Immunol · 2008288 citationsRCR 8.4